• Immutep published a medical research presentation on quality-of-life results from its phase II EFTISARC-NEO trial in resectable soft tissue sarcoma.
• The 40-patient trial found no significant quality-of-life deterioration during preoperative treatment with eftilagimod alfa, pembrolizumab and radiotherapy.
• Role functioning improved 12.7 points following treatment; social functioning rose 8.1 points, both statistically significant.
• Fatigue decreased significantly by up to 14.2 points during therapy (p = 0.001).
• The quality-of-life summary score improved 6.0 points following treatment (p = 0.008), while general health status remained stable.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.